Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT3 | P42568 | 1/20 | 0.36 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571074 | 0.87 | KDM4E (0.37) | MLLT3MLLT1RIPK2CD38ALDH1A1 | |
| SCHEMBL1358286 | 0.85 | MLLT3 (0.40) | MLLT3MLLT1RIPK2CD38ALDH1A1 | |
| SCHEMBL8997908 | 0.80 | MLLT3 (0.39) | MLLT3MLLT1RIPK2CD38ALDH1A1 | |
| SCHEMBL8998112 | 0.76 | MLLT3 (0.40) | MLLT3MLLT1RIPK2ALDH1A1NPC1 | |
| SCHEMBL13953887 | 0.73 | NOTUM (0.34) | ALDH1A1NPC1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL8998142 | 0.73 | NOTUM (0.35) | SMN1; SMN2MAPT | |
| SCHEMBL8998114 | 0.73 | CD38 (0.37) | MLLT3MLLT1RIPK2CD38ALDH1A1 | |
| SCHEMBL8998146 | 0.73 | PDE2A (0.39) | ALDH1A1MAPT | |
| SCHEMBL8998536 | 0.73 | L3MBTL1 (0.42) | ALDH1A1CYP3A4SMN1; SMN2USP2 | |
| SCHEMBL8998426 | 0.72 | SLC40A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193352-B2 | 2-(3-Ethyl-ureido)-6-pyridin-3-yl-3H-benzoimidazole-4-carboxylic acid methyl ester; for treating bacterial infections in mammals; useful in treating or lessening severity of urinary tract infections, pneumonia, prostatitis, skin and soft tissue infections, intra-abdominal infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100063069-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063069-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | MLLT3 2533/4885MLLT1 1608/4885RIPK2 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.